HuagongsheHuagongshe Chemistry Print Report · For research reference only
4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholine → 4-(2-(2-(azetidin-1-yl)-1H-benzo[d]imidazol-1-yl)-8-((4-tert-butylpiperazin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine
Participants
| Role | Name | HCID | Charge |
|---|---|---|---|
| Reactant | 4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholine | HCID 59605470 | — |
| Reactant | 2-(azetidin-1-yl)-1H-benzo[d]imidazole | HCID 59605883 | — |
| Product | 4-(2-(2-(azetidin-1-yl)-1H-benzo[d]imidazol-1-yl)-8-((4-tert-butylpiperazin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine | HCID 59605416 | — |
Reaction Steps
4-(8-((4-tert-butylpiperazin-1-yl)methyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholine (75 mg) was reacted with 2-(azetidin-1-yl)-1H-benzo[d]imidazole (33 mg) via General Procedure for Buchwald coupling to give 36.1 mg 454 following reverse phase purification. MS (Q1) 545.4 (M)+
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| Patent number | US08394796B2 |
| Source dataset | uspto-grants-2013_03 |
| ORD ID | ord-389840ea86e140c0afd2351ad9fc3236 |
| Source note | uspto-grants-2013_03 |